Last reviewed · How we verify
CSF-1 Component #2
CSF-1 Component #2 is a protein that modulates immune cell function.
CSF-1 Component #2 is a protein that modulates immune cell function. Used for Treatment of autoimmune diseases.
At a glance
| Generic name | CSF-1 Component #2 |
|---|---|
| Sponsor | Orasis Pharmaceuticals Ltd. |
| Target | CSF-1R |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
CSF-1 Component #2 is a component of the colony-stimulating factor 1 (CSF-1) protein, which plays a crucial role in the regulation of immune cell function, including the proliferation and differentiation of macrophages and dendritic cells. By modulating the activity of these cells, CSF-1 Component #2 may help to restore balance to the immune system and reduce inflammation.
Approved indications
- Treatment of autoimmune diseases
Common side effects
- Injection site reactions
Key clinical trials
- Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma (PHASE1, PHASE2)
- PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors (PHASE1, PHASE2)
- Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401) (PHASE2)
- A Multi-Center, Double-Masked Evaluation of the Efficacy and Safety of CSF-1 in the Treatment of Presbyopia (PHASE2)
- Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma (PHASE2)
- Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant (PHASE2)
- Vaccine Therapy in Treating Patients With Stage IV Breast Cancer (PHASE1, PHASE2)
- Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |